A New Approach to Cancer

Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. Harnessing unique innovations from our founders, partners, and the world-class scientists at TIO Discovery, we are advancing a pipeline of novel clinical candidates with pan-cancer potential aimed at genomic instability and previously untapped immuno-oncology targets.


Exploiting cancer cells’ vunerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with highly aggressive cancers.


Unique drug discovery engine from world-class founders and team efficiently and effectively using non-dilutive capital to advance multiple clinical candidates


3 novel clinical candidates with pan-cancer potential focused on genomic instability and untapped immuno-oncology targets with multiple expected upcoming milestones

TIO Discovery – First-in Class Therapies. Efficiently

TIO Discovery is TIO Bioventures’ discovery engine. With operations in Boston, New York, San Francisco, Toronto, and Hong Kong, TIO Discovery is a uniquely designed, lean but fully self-sufficient drug discovery and development organization which currently forms the foundation of TIO Bioventures portfolio companies. The team of seasoned entrepreneurs and proven leaders employed at TIO Discovery, all with commercial success in drug development, are uniquely engaged in the management and oversight of the TIO family of companies, with the goal to rapidly and efficiently advance breakthrough medicines.

Through highly efficient and flexible resourcing and out-sourcing strategies, TIO Discovery is designed to bring first in class therapies into the family of TIO-founded companies and to optimize their strategy and tactics of clinical development in the path to value. In collaboration with the laboratories of renowned innovators from around the globe, such as celebrated scientist and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) co-founder Dr. Tak Mak, TIO Discovery has validated multiple novel targets, has developed next-generation biologic and T cell therapy platforms, and has advanced therapeutic candidates into clinical development. The discovery and development engine is multi-functional, featuring highly experienced experts in both drug discovery and early to late stage clinical development, with the capabilities to support the TIO Bioventures companies in a flexible, cost-efficient manner.

Targeting Unmet Needs in Highly Aggressive Cancers

TNBC – triple negative breast cancer (estrogen receptor negative, progesterone receptor negative and HER2 negative)

  • 15-20% of all breast cancers / ~40K new cases/year in the U.S.
  • 5-year survival rate 77% vs. 93% for other forms of breast cancer
  • No targeted therapies approved

AML – acute myeloid leukemia

  • 32% of adult leukemia cases / ~ 20K new cases/year in the U.S.
  • 5-year survival rate 28% / ~10K deaths/year in the U.S.
  • TP53 mutated, complex karyotype AML = 5-year survival 2-3%
  • No targeted therapies approved


Michael Tusche, PhD MBA

Co-Chief Executive Officer

In addition to a being a partner at TIO Bioventures, Dr. Michael Tusche brings over a decade of experience as a scientist, investor, and entrepreneur to his role of co-CEO of Treadwell Therapeutics. Previously, Michael was the Chief Scientific Officer and Co-Founder of Nirsum Laboratories, Inc., a startup Biotechnology company developing small molecule therapeutics for Neuroscience indications. At Nirsum, Dr. Tusche was the Co-inventor of the company’s foundational Intellectual Property and a Principal Investigator of an NIH/NIDA grant, funding the company’s operations into mid-stage clinical studies. Prior to Nirsum, Michael was the Senior Biotechnology Analyst at Mountain Brook Capital Management, LLC, a Healthcare focused Long/Short equity only Hedge Fund, where his focus was Investments in publicly listed Biopharmaceutical companies. Before Mountain Brook, Dr. Tusche was an Associate at MLV and Co., a boutique investment bank with a focus on capital raising and advisory work for Life Science based companies. Dr. Tusche also led Biologic drug discovery at the Campbell Family Institute in Toronto, Canada, where he managed a multidisciplinary R&D team in the pre-clinical development and validation of novel drug candidates. Michael started his career as a Scientist in drug discovery at Bayer AG in Japan, where he worked on early stage development of small molecule GPCR antagonists for allergic and inflammatory diseases.

Dr. Tusche received his B.Sc. (with Distinction) in Biochemistry from the University of Victoria. He also received a Ph.D. in Immunology from the University of Toronto where he trained in the laboratory of Dr. Tak Mak. Michael received his M.B.A. from the University of Toronto. He is co-author on several peer-reviewed publications, the recipient of numerous scientific and business awards, and named inventor on issued US patents focusing on small molecule and biologic therapeutics.

Shane Burgess, OD, MBA
Co-Chief Executive Officer

A co-founder and managing director of TIO Bioventures, Dr. Shane Burgess brings significant entrepreneurial and management experience in the healthcare industry to his role as Co-CEO of Treadwell. In addition to co-founding several successful international companies, including FYiDoctors, Shane has held senior executive roles in organizations ranging from seed-funded start-ups to leading, global companies and has consistently established and led high performing teams to drive innovative product development, deliver entity-wide strategic and operational effectiveness, and achieve transformative corporate and business development results. Shane holds Bachelor of Science and Doctor of Optometry degrees from Canada’s University of Waterloo, and an MBA from Simon Fraser University.

Mark R. Bray, PhD
Co-Founder and Chief Scientific Officer

A partner in TIO Bioventures, Dr. Bray is a co-founder of Treadwell and currently serves as Chief Scientific Officer. Dr. Bray played an integral role in the discovery and development of the company’s current clinical pipeline,  and leads the Canadian site of TIO Bioventures’ research and development entity, TIO Discovery. Mark has more than 20 years of experience in drug discovery, preclinical drug development, and research project management in environments ranging from entrepreneurial start-ups to large biopharmaceutical companies. From 2012 to the present, he has directed all activities of the multi-disciplinary drug discovery and development team at Campbell Family Institute for Breast Cancer Research (CFIBCR), University Health Network at Princess Margaret Cancer Centre, where multiple programs have been advanced from discovery to clinical trials under his leadership. Prior to joining the CFIBCR, Mark was Vice President, Research for Rockville, MD-based EntreMed, Inc (now CASI Pharmaceuticals). Dr. Bray co-founded Miikana Therapeutics in 2002, along with Drs. Tak Mak and Gail Eckhardt, and served as Director of Research of Miikana Therapeutics until the company was acquired by EntreMed in 2006. Mark previously held positions at Amgen, acting as scientific liaison between the Toronto-based Amgen Research Institute (ARI) and Amgen’s California headquarters, initiating and leading early stage discovery programs into therapeutic development. He holds a Bachelor of Science degree in microbiology from the University of Toronto and MSc and PhD degrees in microbiology, protein chemistry and enzymology from the University of Guelph.

Ryan Dietz, JD
VP, Corporate Development

Ryan Dietz currently serves as VP, Corporate Development at Treadwell, while also a partner in TIO Bioventures. He brings more than 20 years of experience to the role, having deep experience in technology evaluation, intellectual property generation, licensing and partnering transactions, and company formation. Prior to joining TIO, Ryan was a licensing executive with Boston Children’s Hospital, where he oversaw the hospital’s two largest research programs across all stages of development. During his industry career, Ryan led technology development and intellectual property generation efforts for various prominent start-up biotechnology and pharmaceutical companies including Moderna, Scholar Rock, Magenta Therapeutics, and Morphic Therapeutic. Each of these companies successfully completed IPOs in 2018 or 2019, including the largest IPO in biotechnology history with Moderna raising $620M at a $7.5B valuation. Ryan also has extensive business development and alliance management experience and is an inventor and developer of multiple consumer products for musicians. He holds a Bachelor of Arts degree in psychology and criminal justice from Indiana University Bloomington, and a JD in intellectual property and licensing from Suffolk University Law School.

Tak Wah Mak, PhD

Perhaps best known for discovering and first cloning the T cell receptor and identifying the function of the CTLA-4 immune checkpoint protein, Dr. Tak Wah Mak is recognized as one of the world’s leading scientists. As Director of the Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre and through his role at TIO Bioventures, Tak is continuing his quest to study and find cures for the most complex forms of cancer. He has had a uniquely distinguished career in the life science industry having participated in the development of multiple blockbuster oncology therapeutics while Vice President of Research at Amgen, having decades of experience advising global life science venture funds, including Lombard Odier and Aravis, and having co-founded and led multiple successful biopharmaceutical companies, including Agios Pharmaceuticals and Miikana Therapeutics. Tak is a Fellow of the Royal Society of Canada, a recipient of the Gairdner International Award for Science, an Officer of the Order of Canada, and a laureate of the Canadian Medical Hall of Fame (2009). The author of more than 900 scientific publications, Tak has received many distinguished prizes, including the Sloan Award (1996), the Novartis Prize in Immunology (1998), and the Paul Ehrlich Prize (2004). He currently serves on multiple scientific advisory boards, most notably Stand Up To Cancer.